Press Releases
Valiltramiprosate is an investigational agent and not approved for use anywhere in the world. Statements in news stories may be aspirational.
Alzheon Scientists Discover Endogenous Substance in Human Brain that Inhibits Formation of Toxic Beta Amyloid Oligomers, Key Driver of Alzheimer’s Disease
Publication Details Discovery of 3-Sulfopropanoic Acid, the Primary Metabolite of Tramiprosate and its Prodrug ALZ-801, in Cerebrospinal Fluid of Healthy Subjects as well as Alzheimer’s Patients [...]
Alzheon Appoints Former IVAX President, Neil Flanzraich, JD, as Vice Chairman of Board of Directors
Framingham, Mass. – August 6, 2018 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other [...]
Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease, Further Supporting Precision Medicine Approach and Planned Confirmatory Clinical Trial with ALZ-801
Presentation at the Alzheimer’s Association International Conference Details Patient Responder Analyses on Key Clinical Outcomes FRAMINGHAM, Mass., July 23, 2018 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused [...]
FDA Grants Fast Track Designation to Alzheon’s ALZ-801 Development Program for the Treatment of Alzheimer’s Disease
Company’s Phase 3 Clinical Program Pioneers a Precision Medicine Approach in Alzheimer’s Disease FRAMINGHAM, Mass. – October 24, 2017 – Alzheon, Inc., a clinical stage biopharmaceutical [...]
Alzheon Publishes Clinical Results that Demonstrate Safety Profile and Efficacy Potential of ALZ-801 as an Orally-Available Precision Medicine to Treat Alzheimer’s Disease
Results Support Pivotal Phase 3 Development of ALZ-801 in Genetically-Defined APOE4/4 Patients and Further Expansion to Additional Alzheimer’s PopulationsFRAMINGHAM, Mass., October 24, 2017 – Alzheon, Inc., today [...]
Alzheon Publishes New Analyses Showing Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients at the Mild Stage of Alzheimer’s Disease; Clinical Effects Suggest Disease Modification Potential and Align with Preclinical Effects on Beta Amyloid Oligomer Formation
Analyses from Phase 3 Studies Published in The Journal of the Prevention of Alzheimer’s Disease Show Strongest Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients with Mild AD [...]
Alzheon Scientists Discover Novel Therapeutic Mechanism of Inhibition of Formation of Toxic Beta Amyloid Oligomers, Key Driver of Alzheimer’s Disease Pathogenesis
Published Data Shows that Novel ‘Enveloping’ Mechanism of Tramiprosate Modulates Misfolding of Aß42 Amyloid and Prevents Oligomer Formation Early in Amyloid Aggregation Cascade Pharmacokinetic Analyses Confirm Tramiprosate [...]
Alzheon Publishes New Analyses from Phase 3 Studies Showing Clinical Benefit of Tramiprosate in Alzheimer’s Patients Who Are Carriers of APOE4, the Major Genetic Risk Factor in up to 65 Percent of Alzheimer’s Patients
Data published in The Journal of the Prevention of Alzheimer’s Disease is the first report to associate efficacy of an amyloid-targeted drug with the number of [...]
Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimer’s Patients with APOE4/4 Homozygous Genotype
Pharmacokinetic and Safety Data from Phase 1b Studies with ALZ-801, an Optimized Prodrug of Tramiprosate, Presented at the Alzheimer's Association International Conference FRAMINGHAM, Mass., July 25, [...]
Alzheon Announces Efficacy Analyses of Prior Tramiprosate Phase 3 Studies Showing Clinically Meaningful Benefits on Key Clinical Endpoints in Alzheimer’s Disease Patients with APOE4 Genotype
Results Support Advancement of ALZ‐801 into Pivotal Clinical Studies in APOE4/4 Homozygous Subjects with Mild to Moderate Alzheimer’s Disease Data Presented at the 14th Annual International [...]
Newsletter
Sign up for updates
Get the latest Alzheon news in your inbox.
Not seeing the signup form? An ad or privacy blocker may be hiding it – email info@alzheon.com and we’ll add you to the list.
